1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

PFE offered AGN $160B in 2015...now ABBV is paying $63?

Discussion in 'Allergan' started by anonymous, Jun 25, 2019 at 9:45 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    $10bb of the $40bb was in Teva stock...Allergan lost a ton of that $10bb value.